Keywords : biosimilar, interferon beta, Monoclonal Antibody, Biopharmaceutical, Erythropoietin, Infliximab, Abciximab, ReliPoietin
This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development....
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: August 2012
- Report size: 46 pages
- Report price: $ 3 800
This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.Reliance Life Sciences has a primary focus on biopharmaceuticals and pharmaceuticals, but also a presence in the wider areas of clinical research services, regenerative medicine, molecular medicine, and biofuels. The overall sales of Reliance Life Sciences totaled $104.7m in FY2011, with approximately 70% coming from biopharmaceutical products.Assess Reliance's portfolio of 7 marketed biosimilars and 20 pipeline products, which includes 3 monoclonal antibody productsSee how the 2007 acquisition of GeneMedix will help diversify Reliance's geographical focus
Biopharmaceutical Industry in India
ABOUT THIS REPORT•Chapter structure - Strategic insight
- Product analysis
- Corporate structure
•Data sourcing
•PharmaVitae Explorer database
EXECUTIVE SUMMARY•Reliance Life Sciences biosimilars overview
•Reliance Life Sciences biosimilars infrastructure
STRATEGIC INSIGHT•Reliance Life Sciences made the strategic acquisition of GeneMedix to penetrate the European markets
•Reliance is focusing on the oncology therapy area and developing a portfolio of MAb biosimilars - Oncology focus
•Reliance Life Sciences biosimilars SWOT analysis - Strengths
- Weaknesses
- Opportunities
- Threats
KEY PRODUCTS•Reliance Life Sciences biosimilars portfolio
•ReliPoietin (epoetin alfa) - Overview
- Erythropoietin market size
- Key competitors
•ReliGrast (filgrastim)Reliance Life Sciences launched biosimilar granulocyte colony-stimulating factor (GCSF) ReliGrast in 2008. It is currently marketed in India and other semi-regulated markets. - Filgrastim and pegfilgrastim market size
- Key competitors
•ReliFeron (interferon alfa-2b) - Overview
- Interferon alfa market size
- Key competitors
•FostiRel (follitropin beta) - Market overview
- Key competitors
•ReliBeta (interferon beta-1a) - Overview
- Interferon beta market size
- Key competitors
- Reliance Life Sciences' other marketed products and biosimilar development
CORPORATE STRUCTURE•Background
•Key corporate developments
•Company structure - Biopharmaceuticals
- Novel therapeutics
- Pharmaceuticals
- Clinical research services
- Regenerative medicine
- Molecular medicine
- Plant biotechnology
- Industrial biotechnology
•Deals and alliances
•Recent developments
APPENDIX•References - Datamonitor reports
•Exchange rates
TABLES
•Table: Reliance Life Sciences biosimilars development and marketing capabilities
•Table: Forecast global sales of infliximab, rituximab, and abciximab ($m), 2011–16
•Table: Reliance Life Sciences – life sciences initiatives
•Table: Reliance Life Sciences – biosimilar/copy-biologic portfolio
•Table: Forecast epoetin sales in the seven major markets ($m), 2011–16
•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic epoetin and darbepoetin drugs
•Table: Forecast filgrastim and pegfilgrastim sales in the seven major markets ($m), 2011–16
•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs
•Table: Forecast interferon alfa and peginterferon alfa sales in the seven major markets ($m), 2011–16
•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon alfa
•Table: Forecast follitropin alfa and beta sales in the seven major markets ($m), 2011–16
•Table: Biosimilar/copy-biologic follitropin drugs, 2012
•Table: Forecast interferon beta sales in the seven major markets ($m), 2011–16
•Table: Reliance Life Sciences – pipeline and marketed biosimilar/copy-biologic interferon beta drugs
•Table: Reliance Life Sciences – monoclonal antibodies under development
•Table: Reliance Life Sciences/GeneMedix deal activity and biosimilar deals, 2000?12
•Table: Exchange rates, 2012
FIGURES
•Figure: The PharmaVitae Explorer
•Figure: Reliance Life Sciences biosimilars overview
•Figure: Mutual benefits through Reliance Life Sciences' acquisition of GeneMedix
•Figure: Reliance Life Sciences – biosimilar and pharmaceutical products and therapy area
•Figure: Reliance Life Sciences SWOT analysis
•Figure: Proportion of government and private health expenditure versus personal disposable income, in India and other major markets, 2009
•Figure: Reliance Life Sciences – revenues, FY2010–12
•Figure: Reliance Life Sciences – revenues, FY2010?12
•Figure: Reliance Life Sciences – company structure
Companies Mentioned
Antares Pharma, Inc., Asian Development Bank, CJ Corporation, Hutchison 3G UK Limited, Janssen Pharmaceuticals, Inc., Merck KGaA, Reliance Industries Limited, Schindler Holding Ltd.
Biopharmaceutical in India
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Biopharmaceutical
- Countries : India
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Biopharmaceutical
- Countries : India
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Biopharmaceutical
- Countries : India
- $ 250
- Industry data
- January 2013
Yearly, From 2002 To 2011
By Business Monitor International
Source: United Nations Comtrade Database DESA/UNSD, BMI
- Industries : Biopharmaceutical
- Countries : India
- Publication date: August 2012
- Report size: 46 pages
- Report price: $ 3 800